Cargando…
302. Using Antiphospholipid Antibody Presence as an Additional Biomarker to Identify COVID-19 Positive Patients with High Risk for Thrombosis
BACKGROUND: Patients who are hospitalized with Coronavirus 2019 (COVID-19) are known to have increased risk for thrombosis. Several mechanisms have been proposed for increased thrombogenesis, including antiphospholipid antibodies (APLs). We sought to better understand the relationship between a comm...
Autores principales: | Hewlett, Jennifer R, Du, Jing, Lee, M Sung, McLeod, Gavin, Archer, Herbert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644022/ http://dx.doi.org/10.1093/ofid/ofab466.504 |
Ejemplares similares
-
Identifying Additional Risk Factors for Thrombosis and Pregnancy Morbidities Among Antiphospholipid Antibodies Carriers
por: Zuo, Yu, et al.
Publicado: (2018) -
Antiphospholipid antibodies and thrombosis: pathogenesis of antiphospholipid syndrome
por: Koike, T
Publicado: (2003) -
P1681: FXI LEVELS AS INDEPENDENT RISK FACTOR FOR THROMBOSIS/OBSTETRIC EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
por: De La Morena-Barrio, M. E., et al.
Publicado: (2022) -
Loss of antiphospholipid antibody positivity post-thrombosis in SLE
por: Khawaja, Muznay, et al.
Publicado: (2020) -
LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
por: Ochoa, Eguzkine, et al.
Publicado: (2016)